Healthcare Services

Lung Cancer Liquid Biopsy Market Developments Influencing Industry Expansion Through 2030

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Lung Cancer Liquid Biopsy Market Become By 2030 Compared To 2026?

The lung cancer liquid biopsy market has witnessed rapid growth in recent years. Its value is projected to rise from $1.12 billion in 2025 to $1.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.0%. Several factors contributed to its historical expansion, including increasing lung cancer incidence rates, the limitations inherent in tissue biopsy procedures, advancements within molecular diagnostics, the widespread availability of circulating biomarker technologies, and the overall growth in oncology research activities.

The lung cancer liquid biopsy market size is projected for significant expansion in the coming years. This market is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. Factors driving this growth during the forecast period include the increasing demand for precision oncology solutions, the broadening of liquid biopsy clinical applications, the rising adoption of companion diagnostics, the expanding integration of AI-driven data analysis, and an intensified focus on early cancer screening programs. Key trends identified for the forecast period encompass the increasing acceptance of non-invasive diagnostic techniques, the growing utilization of NGS-based liquid biopsy tests, an escalating demand for early cancer detection, the expansion of personalized oncology diagnostics, and improved integration of bioinformatics platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp

What Influential Factors Are Boosting The Lung Cancer Liquid Biopsy Market Demand?

The rising occurrence of lung cancer is expected to propel the future growth of the lung cancer liquid biopsy market. Lung cancer is a medical condition defined by the uncontrolled multiplication of abnormal cells in the lungs, often triggered by smoking and environmental exposures. The primary reason for the increase in lung cancer cases is ongoing tobacco use, as smoking introduces carcinogens into the lungs that stimulate abnormal cell development. Lung cancer liquid biopsy aids by identifying cancer-related genetic mutations and tumor DNA from a blood sample, which enables early diagnosis, selection of suitable treatment, and monitoring of disease advancement or response to therapy. For instance, in January 2023, according to a report published by the American Cancer Society (ACS), a U.S.-based nonprofit organization, it was estimated that in 2023, 238,340 individuals, including 117,550 men and 120,790 women, would be diagnosed with lung cancer, and 127,070 people are expected to die from the disease. Therefore, the increasing incidence of lung cancer is driving the growth of the lung cancer liquid biopsy market.

What Are The Major Segment Categories Within The Lung Cancer Liquid Biopsy Market?

The lung cancer liquid biopsy market covered in this report is segmented –

1) By Product: Instruments, Consumables, Kits And Reagents, Software And Services

2) By Technology: Multi-Gene-Parallel Analysis (Ngs), Single-Gene Analysis (PCR Microarrays)

3) By Biomarker: Cell-Free Deoxyribonucleic Acid, Circulating Tumor Deoxyribonucleic Acid, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers

4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications

5) By End User: Diagnostics And Imaging Centres, Hospitals, Academics And Research Centers, Other End Users

Subsegments:

1) By Instruments: PCR Instruments, Microarray Instruments, Next-Generation Sequencing (NGS) Instruments

2) By Consumables Kits And Reagents: Sample Collection Kits, Amplification Reagents, Sequencing Reagents

3) By Software And Services: Data Analysis Software, Cloud-Based Services, Bioinformatics Tools

What Trends Are Shaping The Lung Cancer Liquid Biopsy Market Structure?

Major companies in the lung cancer liquid biopsy market are concentrating on advancing technologies, such as blood-based lung cancer screening tests, to improve early detection capabilities, enhance diagnostic precision, and allow for non-invasive, continuous monitoring of tumor progression and treatment outcomes. A blood-based lung cancer screening test represents a non-invasive method that examines biomarkers in the bloodstream to identify lung cancer at an early stage. For instance, in October 2023, DELFI Diagnostics Inc., a US-based biotechnology firm, introduced FirstLook Lung, a blood-based liquid biopsy test specifically developed to assist in the early detection of lung cancer. This test utilizes fragmentomics to pinpoint early lung cancer with high sensitivity and a 99.8% negative predictive value, providing an accessible and convenient initial step for at-risk individuals. Its aim is to boost early detection, increase screening participation, and help channel additional imaging resources to those who would most likely benefit.

Who Are The Firms Contributing To The Lung Cancer Liquid Biopsy Market Ecosystem?

Major companies operating in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation

Access The Complete Lung Cancer Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report

Which Area Represents The Largest Portion Of The Lung Cancer Liquid Biopsy Market?

North America was the largest region in the lung cancer liquid biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lung cancer liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lung Cancer Liquid Biopsy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24593&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Liquid Biopsy Market 2026, By The Business Research Company

Lung Cancer Diagnostic And Screening Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Liquid Biopsy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Lung Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795